About SSI Diagnostica Group
SSI Diagnostica Group, a global leader in infectious disease clinical diagnostics, was originally established as a division of the prestigious Danish National Reference Center – Statens Serum Institut. Currently held by Adelis Equity, the SSI Diagnostica Group has grown significantly and now has its headquarters in Hillerød, Denmark. The company employs over 600 people across the globe and offers innovative solutions for disease surveillance, diagnosis, outbreak investigation, and quality control in three key areas: gastric, respiratory, and bloodborne diseases.
With administrative and manufacturing facilities located in Denmark, the United States, and China, and a strong global network of distribution partners, the SSI Diagnostica Group continues to build its position as a leading supplier of reagents and in vitro diagnostic (IVD) products worldwide.
Our Strong Portfolio
The companies within the SSI Diagnostica Group specialize in the production of an extensive range of polyclonal and monoclonal antibodies, high-titer antisera, and antigens. This manufacturing process is overseen by experts in the field and utilizes well-characterized strains to ensure the highest quality and reliability.
The SSI Diagnostica Group is a trusted provider of high-quality antisera for vaccine development and quality control, having served vaccine manufacturers worldwide for decades.
The SSI Diagnostica Group in vitro diagnostic (IVD) portfolio features state-of-the-art diagnostic kits and consumables, including culture media, lateral flow, rapid EIA, and ELISA platforms.
The SSI Diagnostica Group comprises companies with a rich heritage in laboratory testing and deeply rooted partnerships in the vaccine and IVD sectors. For over a century, our DNA has been characterized by robust technical expertise and a commitment to scientific collaboration.
Get in touch
Please, reach out if you have a question, comment or request.